Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Drug Repurposing Trial of Vortioxetine for the Treatment of Patients With Newly Diagnosed Glioblastoma

NCT07284628 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.

NCT NCT07284628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07284628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Drug Repurposing Trial of Vortioxetine for the Treatment of Patients With Newly Diagnosed Glioblastoma
Lead sponsor
University of Zurich
Phase
Phase 2
Overall status
Recruiting
Start date
June 24, 2026
Completion date
June 30, 2029
Enrollment
78 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma